-+ 0.00%
-+ 0.00%
-+ 0.00%

Reported Saturday, Johnson & Johnson Says Patient Insights From Phase 2 DAHLIAS Study Helped Inform Phase 3 Nipocalimab Design, With 73.5% Of Interviewed Patients Satisfied Or Very Satisfied With Treatment In Sjögren’s Disease

Benzinga·11/09/2026 08:38:19
Listen to the news
  • New patient experience dataa to be presented at ACR 2026 show mouth dryness was reported as the most important symptom to improve, followed by eye dryness, fatigue and joint pain
  • Patient insights complement Phase 2 study results demonstrating a 50% increase in saliva productionb in more than twice as many patients on nipocalimab compared to placeboc 
  • Two Phase 3 studies are ongoing, evaluating nipocalimab in Sjögren's disease including these measures critical to patients